OncoMatch/Clinical Trials/NCT06048094

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Is NCT06048094 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 18F fluciclovine for brain metastases.

Phase 1RecruitingBaptist Health South FloridaNCT06048094Data as of May 2026

Treatment: 18F fluciclovine — This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: whole-brain radiation therapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Miami Cancer Institute · Miami, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify